This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (Original) An immunogenic composition comprising a combination of *Chlamydia trachomatis* antigens, said combination consisting of two, three, four or all five *Chlamydia trachomatis* antigens of a first antigen group, said first antigen group consisting of PepA, LcrE, ArtJ, DnaK and CT398.
- 2. (Original) The composition of claim 1, wherein said combination consists of PepA, LcrE, ArtJ, DnaK and CT398.
- 3. (Original) The composition of claim 1, wherein said combination includes LcrE.
- 4. (Original) The composition of claim 1, said composition further comprising one or more immunoregulatory agents.
- 5. (Original) The composition of claim 4, wherein said one or more immunoregulatory agents include an adjuvant.
- 6. (Original) The composition of claim 5, wherein said adjuvant is selected from the group consisting of a TH1 adjuvant and a TH2 adjuvant.
- 7. (Original) The composition of claim 5, wherein the adjuvant is selected from the group consisting of aluminum salts and oligonucleotides comprising CpG motifs.
- 8. (Original) An immunogenic composition comprising a combination of Chlamydia trachomatis antigens, said combination consisting of two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen *Chlamydia trachomatis* antigens of a second antigen group, said second antigen group consisting PepA, LcrE, ArtJ, DnaK, CT398, OmpH-like, L7/L12, OmcA, AtoS, CT547, Enolase, HtrA and MurG.

- 9. (Original) The immunogenic composition of claim 8, wherein said combination includes one or more of the group consisting of PepA, LcrE, ArtJ, DnaK, OmpH-like and CT398.
- 10. (Original) The immunogenic composition of claim 8, wherein said combination includes LcrE.
- 11. (Original) The immunogenic composition of claim 8, wherein said combination includes OmpH-like protein.
- 12. (Original) The composition of claim 8, said composition further comprising one or more immunoregulatory agents.
- 13. (Original) The composition of claim 12, wherein said one or more immunoregulatory agents include an adjuvant.
- 14. (Original) The composition of claim 13, wherein said adjuvant is selected from the group consisting of a TH1 adjuvant and a TH2 adjuvant.
- 15. (Original) The composition of claim 13, wherein the adjuvant is selected from the group consisting of aluminum salts and oligonucleotides comprising CpG motifs.
- 16. (Original) A vaccine comprising the immunogenic composition of any one of the previous claims.
- 17. (Currently amended) A method of preparing a medicament for the prevention or treatment of Chlamydia trachomatis infection comprising providing Use of the immunogenic composition according to any one of claim 1-15-or a vaccine according to claim 1-6 in the preparation of a medicament for the prevention or treatment of a Chlamydia trachomatis infection.
- 18. (Currently amended) A method of neutralizing a *Chlamydia trachomatis* infection in a mammal comprising the step of administering to the mammal an effective amount of the

composition of any one of claims 1 to 15 or the vaccine according to claim 16 or antibodies which recognize an immunogenic composition as defined in any one of claims 1 to 15.

- 19. (Currently amended) A method of raising an immune response in a mammal against a *Chlamydia trachomatis* infection comprising administering to the mammal an effective amount of the composition of any one of claims 1 to 15 or the vaccine according to claim 16 or antibodies which recognizes an immunogenic composition as defined in any one of claims 1 to 15.
- 20. (Original) The method of claim 19, wherein said composition elicits an enhanced TH1 and TH2 immune response.
- 21. (Currently amended) A method of raising *Chlamydia trachomatis* specific antibodies comprising administering to the <u>a</u> mammal an effective amount of the composition of any one of claims 1 to 15 or the vaccine according to claim 16 or an antibody which recognizes a protein as defined in any one of claims 1 to 15.
- 22. (Currently amended) An immunogenic composition comprising a combination of *Chlamydia trachomatis* antigens, said combination consisting of two, three, four or all five *Chlamydia trachomatis* antigens of a first antigen group, said first antigen group consisting of PepA, LcrE, ArtJ, DnaK and CT398, wherein said composition further emprising comprises one or more immunoregulatory agents.
- 23. (Original) An immunogenic composition comprising an oligonucleotide containing a CpG motif, a mineral salt, and an antigen associated with a sexually transmissible disease.
- 24. (Original) The composition of claim 23, wherein said mineral salt is an aluminum salt.
- 25. (Original) The composition of claim 23, wherein said antigen is a *Chlamydia trachomatis* antigen.

- 26. (New) A method of preparing a medicament for the prevention or treatment of *Chlamydia trachomatis* infection comprising providing a vaccine according to claim 16.
- 27. (New) A method of neutralizing a *Chlamydia trachomatis* infection in a mammal comprising the step of administering to the mammal an effective amount of the vaccine according to claim 16.
- 28. (New) A method of neutralizing a *Chlamydia trachomatis* infection in a mammal comprising the step of administering to the mammal an effective amount of antibodies which recognize an immunogenic composition as defined in any one of claims 1-15.
- 29. (New) A method of raising an immune response in a mammal against a *Chlamydia trachomatis* infection comprising administering to the mammal an effective amount of the vaccine according to claim 16.
- 30. (New) A method of raising an immune response in a mammal against a *Chlamydia trachomatis* infection comprising administering to the mammal an effective amount of an antibody which recognizes an immunogenic composition as defined in any one of claims 1-15.
- 31. (New) A method of raising *Chlamydia trachomatis* specific antibodies comprising administering to a mammal an effective amount of the vaccine according to claim 16.
- 32. (New) A method of raising *Chlamydia trachomatis* specific antibodies comprising administering to a mammal an effective amount of an antibody which recognizes an immunogenic composition as defined in any one of claims 1-15.